|Bid||6.65 x 3000|
|Ask||6.71 x 2900|
|Day's Range||6.31 - 6.99|
|52 Week Range||3.45 - 14.68|
|Beta (5Y Monthly)||0.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.83|
Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.
Today is shaping up negative for Kala Pharmaceuticals, Inc. (NASDAQ:KALA) shareholders, with the analysts delivering a...
Shares of Kala Pharmaceuticals (NASDAQ: KALA) were sinking 17.4% as of 3:30 p.m. EDT on Tuesday. The big drop came after the drugmaker announced FDA approval of Eysuvis for the short-term treatment of dry eye disease. Aren't biotech stocks supposed to go up when they win FDA approval for a drug?